Financial Statements — CMND
Balance Sheet
(in millions USD)| Metric | Q1
2026 | Q3
2025 | Q2
2025 | Q1
2025 |
|---|
| Cash & Equivalents | 9.26 | 3.50 | 4.47 | 5.78 |
| Total Current Assets | 11.02 | 3.82 | 5.02 | 6.41 |
| Total Non-current Assets* | 0.12 | 0.15 | 0.16 | 0.17 |
| Total Assets | 11.14 | 3.97 | 5.18 | 6.58 |
| Total Current Liabilities | 2.91 | 2.90 | 2.88 | 3.72 |
| Total Non-current Liabilities* | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Liabilities | 2.91 | 2.90 | 2.88 | 3.73 |
| Retained Earnings | (31.73) | (27.19) | (25.88) | (25.09) |
| Total Stockholder Equity | 8.24 | 1.07 | 2.30 | 2.85 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q1
2026 | Q3
2025 | Q2
2025 | Q1
2025 |
|---|
| Research & Development | 0.64 | 0.72 | 0.45 | 0.46 |
| Selling, General & Admin | 3.02 | 0.68 | 0.86 | 1.03 |
| Total Operating Expenses | 3.66 | 1.41 | 1.31 | 1.50 |
| Pretax Income | (3.85) | (1.31) | (0.76) | (1.03) |
| Tax Provision | 0.00 | 0.01 | 0.02 | 0.04 |
| Net Income | (3.85) | (3.17) | (1.86) | (1.07) |
| Basic EPS | (3.32) | (0.25) | (0.16) | (0.24) |
| Diluted EPS | (3.32) | (0.25) | (0.16) | (0.24) |
Cash Flow Statement
(in millions USD)| Metric | Q1
2026 | Q3
2025 | Q2
2025 | Q1
2025 |
|---|
| Operating Cash Flow | (2.08) | (3.45) | (2.36) | (1.27) |
| Investing Cash Flow | -- | (0.02) | (0.13) | 0.07 |
| Financing Cash Flow | 7.42 | 0.38 | 0.39 | 0.40 |
